Ross, F. M., Chiecchio, L., Dagrada, G., Protheroe, R. K. M., Stockley, D. M., Harrison, C. J., Cross, N. C. P., Szubert, A. J., Drayson, M. T., Morgan, G. J., UK Myeloma Forum, [Group Author] (2010) The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95 (7). pp. 1221-1225. ISSN 0390-6078

Full text not available from this repository.

Abstract

A large series of plasma cell dyscrasias (n=2207) was examined for translocations which deregulate the MAF genes, t(14;20)(q32;q12) and t(14;16)(q32;q23), and their disease behavior was compared to a group characterized by the t(4;14)(p16;q32) where CCND2 is also up-regulated. The t(14;20) showed low prevalence in myeloma (27/1830, 1.5%) and smoldering myeloma (1/148, <1%) with a higher incidence in MGUS (9/193, 5% P=0.005). Strong associations. with del(13) (76%), non-hyperdiploidy (83%) and gain of 1q (58%) were seen but no association with an IgA M-protein or absence of bone disease was noted. All three translocations were associated with poor outcome in myeloma, but strikingly all t(14;20) MGUS/smoldering myeloma cases (n=10) had stable, low level disease. In contrast, the 10 t(14;16) and 25 t(4;14) MGUS/smoldering myeloma cases were associated with both evolving and non-evolving disease. None of the associated genetic abnormalities helped to predict for progression from MGUS or smoldering myeloma. (Clinicaltrials.gov identifier: ISRCTN 68454111; UKCRN ID 1176)

Item Type:	Article
Authors (ICR Faculty only):	Morgan, Gareth
All Authors:	Ross, F. M., Chiecchio, L., Dagrada, G., Protheroe, R. K. M., Stockley, D. M., Harrison, C. J., Cross, N. C. P., Szubert, A. J., Drayson, M. T., Morgan, G. J., UK Myeloma Forum, [Group Author]
Uncontrolled Keywords:	plasma cell; myeloma; MGUS; chromosome abnormality; disease progression;PRECEDES MULTIPLE-MYELOMA; GENETIC ABNORMALITIES; T(4/14)(P16.3,Q32); HYBRIDIZATION; PATHOGENESIS; CYTOGENETICS; SUBGROUPS; DELETION; EVENTS
Funding Acknowledgement:	Leukaemia Research
Funding Text:	We thank Leukaemia Research for funding this work, Catherine Stacey-Richardson and the referring clinicians and their research nurses who have provided clinical details, and Faith Davies, Sue Bell and Walter Gregory for various aspects of the Myeloma IX trial.
Research teams:	ICR divisions > Clinical Studies > Molecular Haematology (including Cytogenetics Group and Cell Markers) ICR divisions > Molecular Pathology > Molecular Haematology (including Cytogenetics Group and Cell Markers) Clinical Units > Haemato-Oncology Unit
Depositing User:	Users 10 not found.
Date Deposited:	30 Jul 2010 08:49
Last Modified:	30 Jul 2010 08:49
URI:	http://publications.icr.ac.uk/id/eprint/9781

Actions (login required)

View Item